FNY Investment Advisers LLC Buys 6,481 Shares of OncoCyte Co. (NASDAQ:OCX)

FNY Investment Advisers LLC increased its stake in shares of OncoCyte Co. (NASDAQ:OCX) by 15.1% during the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 49,377 shares of the company’s stock after acquiring an additional 6,481 shares during the period. FNY Investment Advisers LLC’s holdings in OncoCyte were worth $117,000 as of its most recent filing with the SEC.

Separately, Geode Capital Management LLC boosted its position in OncoCyte by 12.2% during the third quarter. Geode Capital Management LLC now owns 103,980 shares of the company’s stock worth $296,000 after purchasing an additional 11,289 shares during the period. 55.35% of the stock is currently owned by institutional investors.

OncoCyte Stock Up 3.4 %

Shares of NASDAQ OCX opened at $2.15 on Wednesday. OncoCyte Co. has a 12 month low of $1.97 and a 12 month high of $3.57. The business’s 50 day moving average is $2.45 and its two-hundred day moving average is $2.86.

OncoCyte (NASDAQ:OCX) last announced its earnings results on Tuesday, November 12th. The company reported ($0.98) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.44) by ($0.54). OncoCyte had a negative return on equity of 269.32% and a negative net margin of 6,122.29%. The company had revenue of $0.12 million for the quarter. During the same quarter in the prior year, the business earned ($0.57) earnings per share. On average, equities research analysts expect that OncoCyte Co. will post -2.57 EPS for the current year.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on the stock. Needham & Company LLC reissued a “buy” rating and issued a $4.25 price target on shares of OncoCyte in a research report on Wednesday, November 13th. StockNews.com began coverage on shares of OncoCyte in a report on Monday. They issued a “sell” rating on the stock.

Insider Activity at OncoCyte

In other OncoCyte news, Director Andrew Arno purchased 12,500 shares of the stock in a transaction on Thursday, December 26th. The shares were purchased at an average price of $2.11 per share, with a total value of $26,375.00. Following the acquisition, the director now directly owns 81,554 shares of the company’s stock, valued at $172,078.94. This represents a 18.10 % increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, major shareholder Patrick W. Smith acquired 90,219 shares of OncoCyte stock in a transaction dated Thursday, December 26th. The shares were acquired at an average cost of $2.13 per share, with a total value of $192,166.47. Following the completion of the acquisition, the insider now directly owns 1,773,903 shares in the company, valued at $3,778,413.39. This trade represents a 5.36 % increase in their position. The disclosure for this purchase can be found here. Over the last 90 days, insiders purchased 122,719 shares of company stock worth $264,341. Company insiders own 1.58% of the company’s stock.

OncoCyte Company Profile

OncoCyte Corporation, a precision diagnostics company, focuses on development and commercialization of proprietary tests in the United States and internationally. The company is developing DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies; DetermaCNI, a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients; and VitaGraft, a blood-based solid organ transplantation monitoring test.